We did it! On Saturday, the Mironid Mudders traded in their lab coats for mud, sweat, and a whole lot of fun at Tough Mudder Scotland to raise funds and awareness for the Polycystic Kidney Disease (PKD) Charity UK (PKD) Charity. A huge well done to the team for their teamwork and determination, and a massive thank you to everyone who came to cheer us on from the sidelines and helped us raise money for the PKD Charity! Learn more about the work we do at Mironid to transform the treatment landscape for patients with ADPKD: https://lnkd.in/ekZ9-J2w #ToughMudder #ADPKD #kidneydisease #RareDisease
About us
Mironid Limited is an innovative new drug discovery company that develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. This allows us to access multiple therapeutic areas for exploitation. Our current drug discovery pipeline is aimed at developing novel treatments for degenerative kidney diseases, chronic inflammatory diseases and cancer.
- Website
-
http://www.mironid.com
External link for Mironid® Limited
- Industry
- Pharmaceutical Manufacturing
- Company size
- 11-50 employees
- Headquarters
- Glasgow
- Type
- Privately Held
- Founded
- 2015
Locations
-
Primary
Get directions
Arbuthnott Building (Hamnett Wing), 161 Cathedral Street
Glasgow, G4 0RE, GB
Employees at Mironid® Limited
Updates
-
Our Lab Manager Jane Findlay recently represented Mironid at the Scientific Laboratory Show and Conference hosted by (SLS) Scientific Laboratory Supplies Ltd. Show and Conference in Nottingham. This event hosted a number of fantastic seminars ranging from lab sustainability to equipment management and was a great opportunity to connect with fellow scientists and discover the latest innovations from the top scientific tools providers. Find out more about what we do at Mironid here: https://lnkd.in/ennSvC9K #ADPKD #kidneydisease #raredisease #biopharma
-
-
The Mironid Mudders are taking on Tough Mudder Scotland on 15th June to raise funds and awareness for the Polycystic Kidney Disease (PKD) Charity UK. We'll be put through our paces – 5 km of mud and 12 hardcore obstacles – but we’re expecting teammate camaraderie to get us all over the finish line! At Mironid, we’re dedicated to developing new therapies to treat ADPKD (Autosomal Dominant Polycystic Kidney Disease) and other rare diseases. ADPKD is a debilitating inherited disease that causes cysts to form in the kidneys over time and leads to kidney damage and failure, at which point patients need dialysis or transplant. ADPKD is the most common inherited kidney disease, with 1 person in every 1,000-2,500 in the UK having ADPKD. The PKD charity is dedicated to improving the lives of individuals & families affected by PKD in the UK. They provide information, advice and personalised support as well as raising the awareness of the burden of PKD. You can donate here: https://lnkd.in/exwvJwtR ! Learn more about the Polycystic Kidney Disease Charity here: https://pkdcharity.org.uk/ #ToughMudder #ADPKD #kidneydisease #raredisease #biopharma
-
We have successfully completed the project funded by Innovate UK titled: ‘Extending Mironid's PDE4 activator programme: Hyperparathyroidism as a second clinical indication’. Our findings were presented at the project close-out meeting by Caitlin Moore, one of our Biology Research Scientists, with others from our team in attendance. Read our blog to find out more about the project and the next steps: https://lnkd.in/eSgcS-gF #HPT #biopharma #drugdevelopment
-
-
Mironid’s CSO Adele Rowley and CMO Catherine (Cass) Kelleher, MD were at the European Renal Association (ERA) Congress over the weekend. Adele gave an oral presentation entitled ‘Targeting cAMP in ADPKD by small molecule activation of long form PDE4 enzymes’ that highlighted data demonstrating that a LoAc® compound resulted in a significant reduction of cAMP levels in a model of Autosomal Dominant Polycystic Kidney Disease (ADPKD), potentially slowing disease progression, preventing the need for dialysis, and offering a potential new treatment option for ADPKD patients. We look forward to progressing a development candidate from our LoAc® programme to advance as a treatment for ADPKD. #ERA24 #Presentation #kidneydisease #raredisease
-
-
Our Chief Scientific Officer Adele Rowley and Chief Medical Officer Catherine (Cass) Kelleher, MD, will be in Stockholm next week at the European Renal Association (ERA) Congress on 23-26 May, presenting data on the effects of our LoAc® compounds on cyst formation in Autosomal Dominant Polycystic Kidney Disease (#ADPKD). Adele will present an abstract titled “Targeting cAMP in ADPKD by small molecule activation of long form PDE4 enzymes” on 25 May in session “FC 14 - Polycystic kidney diseases” in room A5 from 12:00-13:15 CEST. Find out more about Mironid here and get in touch if you would like to connect with Adele or Cass in Stockholm: https://mironid.com/ #ERA24 #kidneydisease #raredisease #biopharma #drugdevelopment
-
Our Chief Executive Officer Neil Wilkie will be in San Sebastien from 12-14 May at Bio€quity Europe, an opportunity to meet with potential investors to discuss the current issues and trends facing the biotech industry and how to rise above the noise to attract the right investors and partnerships. If you would like to meet Neil next week, please get in touch at: [email protected] #kidneydisease #raredisease #biopharma #drugdevelopment
-
-
Tomorrow Adele Rowley, our Chief Scientific Officer, will be presenting at the 2nd ACE Drug Discovery Summit taking place at The Insurance Hall in London. Her presentation will outline our work developing a novel disease modifying treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD). If you would like to learn more, or connect with Adele, please get in touch at [email protected] #2ndADDS2024 #KidneyDisease #RareDisease #Biopharma #DrugDevelopment
-
-
Great to have hosted Charlotte during her placement working within our biology team, well done for all your hard work!
After 6 months of work, I have successfully completed my final year thesis as part of my joint degree in BSc (Hons) Biochemistry and Pharmacology at the University of Strathclyde! I had the unique opportunity to work within the drug development industry at Mironid® Limited. My project explored Mironid’s novel LoAc® compounds in cAMP-driven cystogenesis as a new potential therapeutic treatment for ADPKD. This project provided me with the opportunity to expand my knowledge in the field of drug development, and significantly enhance both my laboratory techniques and analytical skills. I would like to sincerely thank my industrial supervisor, Dr David J P Henderson, for his constant support, in-depth expertise, and encouragement throughout my project. Further to this, I would like to thank the Mironid® Limited biology team for accepting me into their team throughout my time, especially to Dr Tom Moore for his continued support. Additionally, I would like to thank my academic supervisor, Dr Calum Wilson, for his guidance throughout my project and all aspects of my fourth year. The experience I have acquired throughout my project and time at Mironid® Limited I will be able to apply to the next steps of my academic journey upon completion of my degree. Now onto my final exams!
-
-
Today is #WorldKidneyDay, celebrated to raise awareness of the importance of good kidney health and the significant impact of kidney disease, the 10th leading cause of death globally. Mironid is working to transform the treatment landscape for patients with rare kidney disease. Our lead asset is a first-in-class small molecule LoAc® which directly targets the abnormally high kidney cAMP levels that drives cyst formation in Autosomal Dominant Polycystic Kidney Disease (#ADPKD), the most common hereditary kidney condition, with the potential to prevent new cyst formation and halt the growth of existing cysts. Learn more about ADPKD and how Mironid’s LoAc® compound works in this video! #KidneyDisease #RareDisease #Biopharma #DrugDevelopment